DUBLIN, May 16, 2023 /PRNewswire/ — The “Global Menopause Drug Market Size, Trends, and Growth Opportunity, by Stages Type, by Treatment Type, by Product Type, by Route of Administration Types, by End-Users, by Region and Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.
The Global Menopause Drug Market was valued at USD 15.8 billion in 2022 and is expected to expand to USD 24.1 billion in 2030 at a CAGR of 4.61% during the forecast period 2023-2030.
Menopause is a physiological process that occurs when a woman’s body stops producing estrogen hormones and her menstrual cycles generally stopped. It may develop naturally or could be contracted as a result of surgery or chemotherapy. Menopausal women might suffer from hot flashes, exhaustion, depression, lack of concentration, and memory issues.
The increasing incidences of post-menopausal symptoms owing to the shift towards a hectic lifestyle propel the growth of the market.
The growing prevalence of vasomotor and menopausal symptoms like night sweats and hot flashes among women during the menopausal transition and the issues such as mood swings, difficulty in concentrating, and depression act as major factors for the growing market during the forecast period.
Furthermore, rising investment in the treatment of menopausal manifestation boosts the expansion of the market. The growing technological advancements and modernization in the healthcare sector fuel market growth.
The lack of awareness among people regarding menopause drugs and the less consciousness among patients hinders the growth of the market.
Furthermore, the lack of advanced healthcare infrastructure facilities restrains the growth of the global menopause drug market.
North America is likely to dominate the market over the forecast period owing to the high incidences of an unhealthy lifestyle, and the rising introduction of novel drugs in this region.
Asia Pacific is also anticipated to witness substantial growth because of the increasingly vulnerable aging population of menopausal women and the increase in the demand for novel therapies in this region.
Key Question Addressed by the Report
- What are the Key Opportunities in Global Menopause Drug Market?
- What will be the growth rate from 2023 to 2030?
- Which segment/region will have the highest growth?
- What are the factors that will impact/drive the Market?
- What is the role of key players in the value chain?
- Teva Pharmaceutical Industries Ltd
- Eli Lilly and Company
- Pfizer Inc
- Novo Nordisk A/S
- Merck & Co Inc
- Boehringer Ingelheim International GmbH
- Pantarhei Bioscience
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- SHIONOGI & Co Ltd
- BioSyent Inc
- Glenmark Pharmaceuticals Limited
- Ache Laboratorios Farmaceuticos SA
By Stages Type
By Treatment Type
- Non-Hormonal Treatment
- Hormonal Treatment
- Estrogen-Only Medicines
- Progestin-Only Medicines
- Combination Estrogen
- Progestin Medicines
- Herbal Supplements
By Product Type
By Route of Administration Type
- Specialty Clinics
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
For more information about this report visit https://www.researchandmarkets.com/r/79p3zp
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets